Veraxa Biotech Holding AG (NASDAQ:VRXA) Shares Shorted: Short Interest Down 54.3% in October

by · The Cerbat Gem

Veraxa Biotech Holding AG (NASDAQ:VRXA – Get Free Report) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 107,383 shares, a decline of 54.3% from the September 30th total of 235,019 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average daily volume of 421,031 shares, the short-interest ratio is presently 0.3 days.

Veraxa Biotech Price Performance

Shares of VRXA traded up $0.01 during trading hours on Friday, reaching $1.14. The company’s stock had a trading volume of 259,928 shares, compared to its average volume of 308,837. Veraxa Biotech has a 1-year low of $0.95 and a 1-year high of $27.36. The firm has a 50 day moving average of $1.28.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Veraxa Biotech from a “sell” rating to a “hold” rating in a research report on Monday, August 31st.

Check Out Our Latest Analysis on VRXA

Insiders Place Their Bets

In related news, Director Christoph Samuel Ziegler purchased 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 20th. The shares were purchased at an average price of $1.09 per share, with a total value of $32,700.00. Following the purchase, the director owned 37,932 shares of the company’s stock, valued at $41,345.88. This trade represents a 378.21% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Oliver Baumann purchased 50,000 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was bought at an average cost of $1.50 per share, for a total transaction of $75,000.00. Following the purchase, the director directly owned 5,773,618 shares in the company, valued at $8,660,427. This represents a 0.87% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 95,000 shares of company stock worth $125,333 over the last ninety days.

About Veraxa Biotech

(Get Free Report)

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.

Recommended Stories